Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Doxorubicin × NET × Clear all

Phase

Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 224 Breast 137 Sarcoma 80 Other hematologic neoplasm 60 Genitourinary 29 Gastrointestinal 28 Gynecologic 24 CNS 23 Plasma cell 16 Thoracic 7 Head & Neck 7 Other solid neoplasm 5 Endocrine 4 Tumor-Agnostic 3 Myeloid 3 NET 1 Dermatologic 1 Classical hematology 1

Conditions

Neuroendocrine Tumors 1 Neoplasms 1 Neoplasm Metastasis 1

Interventions

lutetium Lu 177 dotatate 18 Everolimus 12 Temozolomide 11 Nivolumab 8 Capecitabine 7 pembrolizumab 6 Sunitinib 6 cabozantinib 5 Magnetic Resonance Spectroscopy 5 lanreotide 4 gallium Ga 68 dotatate 4 Specimen Handling 4 Etoposide 4 177Lu-octreotide, DOTA(0)-Tyr(3)- 4 pazopanib 3 avelumab 3 Octreotide 3 Ipilimumab 3 Injections 3 Fluorodeoxyglucose F18 3 Cyclophosphamide 3 Cisplatin 3 Carboplatin 3 telotristat ethyl 2 surufatinib 2 sintilimab 2 lenvatinib 2 fosbretabulin 2 fludarabine 2 copper dotatate CU-64 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01678664 2024-09-25

EVACEL

Federation Francophone de Cancerologie Digestive

Phase 2 Completed

74 enrolled 10 charts

Neoplasm Metastasis, Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡